176. Hauschild A., Grob J. J., Demidov L. V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C. U., Miller W. H., Jr., Kaempgen E., Martin-Algarra S., Karaszewska B., Mauch C., Chiarion-Sileni V., Martin A. M., Swann S., Haney P., Mirakhur B., Guckert M. E., Goodman V., Chapman P. B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial // Lancet. ‒ 2012. ‒ T. 380, № 9839. ‒ C. 358-65.
177. Long G. V., Weber J. S., Infante J. R., Kim K. B., Daud A., Gonzalez R., Sosman J. A., Hamid O., Schuchter L., Cebon J., Kefford R. F., Lawrence D., Kudchadkar R., Burris H. A., 3rd, Falchook G. S., Algazi A., Lewis K., Puzanov I., Ibrahim N., Sun P., Cunningham E., Kline A. S., Del Buono H., McDowell D. O., Patel K., Flaherty K. T. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib // J Clin Oncol. ‒ 2016.10.1200/JCO.2015.62.9345.
178. McGettigan S. Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma // J Adv Pract Oncol. ‒ 2014. ‒ T. 5, № 3. ‒ C. 211-5.
179. Daud A., Pavlick A. C., Ribas A., Gonzalez R., Lewis K. D., Hamid O., Gajewski T., Puzanov I., Hsu J. J., Koralek D. O., Choong N. W., McArthur G. A. Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma // J Clin Oncol. ‒ 2016. ‒ T. 34, № suppl; abstr 9510.
180. Larkin J., Ascierto P. A., Dreno B., Atkinson V., Liszkay G., Maio M., Mandala M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Sovak M. A., Chang I., Choong N., Hack S. P., McArthur G. A., Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma // N Engl J Med. ‒ 2014. ‒ T. 371, № 20. ‒ C. 1867-76.
181. Ribas A., Gonzalez R., Pavlick A., Hamid O., Gajewski T. F., Daud A., Flaherty L., Logan T., Chmielowski B., Lewis K., Kee D., Boasberg P., Yin M., Chan I., Musib L., Choong N., Puzanov I., McArthur G. A. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study // Lancet Oncol. ‒ 2014. ‒ T. 15, № 9. ‒ C. 954-65.
182. Dummer R., Ascierto P. A., Gogas H. J., Arance A., Mandala M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., Chiarion Sileni V., Dutriaux C., de Groot J. W. B., Yamazaki N., Loquai C., Moutouh-de Parseval L. A., Pickard M. D., Sandor V., Robert C., Flaherty K. T. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial // Lancet Oncol. ‒ 2018.10.1016/S1470-2045(18)30497-2.
183. Kim S., Kim H. T., Suh H. S. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis // J Dermatolog Treat. ‒ 2018. ‒ T. 29, № 3. ‒ C. 314-321.
184. Devji T., Levine O., Neupane B., Beyene J., Xie F. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials // JAMA Oncol. ‒ 2017. ‒ T. 3, № 3. ‒ C. 366-373.
185. Abu-Abed S., Pennell N., Petrella T., Wright F., Seth A., Hanna W. KIT gene mutations and patterns of protein expression in mucosal and acral melanoma // J Cutan Med Surg. ‒ 2012. ‒ T. 16, № 2. ‒ C. 135-42.
186. Abysheva S. N., Iyevleva A. G., Efimova N. V., Mokhina Y. B., Sabirova F. A., Ivantsov A. O., Artemieva A. S., Togo A. V., Moiseyenko V. M., Matsko D. E., Imyanitov E. N. KIT mutations in Russian patients with mucosal melanoma // Melanoma Res. ‒ 2011. ‒ T. 21, № 6. ‒ C. 555-9.
187. Allegra M., Giacchero D., Segalen C., Dumaz N., Butori C., Hofman V., Hofman P., Lacour J. P., Bertolotto C., Bahadoran P., Ballotti R. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib // J Invest Dermatol. ‒ 2014. ‒ T. 134, № 5. ‒ C. 1473-6.
188. Bastian B. C., Esteve-Puig R. Targeting activated KIT signaling for melanoma therapy // J Clin Oncol. ‒ 2013. ‒ T. 31, № 26. ‒ C. 3288-90.
189. Becker J. C., Brocker E. B., Schadendorf D., Ugurel S. Imatinib in melanoma: a selective treatment option based on KIT mutation status? // J Clin Oncol. ‒ 2007. ‒ T. 25, № 7. ‒ C. e9.
190. Carvajal R. D., Antonescu C. R., Wolchok J. D., Chapman P. B., Roman R. A., Teitcher J., Panageas K. S., Busam K. J., Chmielowski B., Lutzky J., Pavlick A. C., Fusco A., Cane L., Takebe N., Vemula S., Bouvier N., Bastian B. C., Schwartz G. K. KIT as a therapeutic target in metastatic melanoma // JAMA. ‒ 2011. ‒ T. 305, № 22. ‒ C. 2327-34.
191. Hodi F. S., Friedlander P., Corless C. L., Heinrich M. C., Mac Rae S., Kruse A., Jagannathan J., Van den Abbeele A. D., Velazquez E. F., Demetri G. D., Fisher D. E. Major response to imatinib mesylate in KIT-mutated melanoma // J Clin Oncol. ‒ 2008. ‒ T. 26, № 12. ‒ C. 2046-51.
192. Dumaz N., Andre J., Sadoux A., Laugier F., Podgorniak M. P., Mourah S., Lebbe C. Driver KIT mutations in melanoma cluster in four hotspots // Melanoma Res. ‒ 2015. ‒ T. 25, № 1. ‒ C. 88-90.
193. Kim J., Lazar A. J., Davies M. A., Homsi J., Papadopoulos N. E., Hwu W. J., Bedikian A. Y., Woodman S. E., Patel S. P., Hwu P., Kim K. B. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma // J Cutan Pathol. ‒ 2012. ‒ T. 39, № 9. ‒ C. 821-5.
194. Lv J., Kong Y., Cai X., Zhou X. Analysis of KIT and BRAF mutations in Chinese melanoma // Pathology. ‒ 2016. ‒ T. 48 Suppl 1. ‒ C. S140.
195. Lyu J., Wu Y., Li C., Wang R., Song H., Ren G., Guo W. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases // J Oral Pathol Med. ‒ 2016. ‒ T. 45, № 4. ‒ C. 295-301.
196. McDonnell K., Betz B., Fullen D., Lao C. D. V559A and N822I double KIT mutant melanoma with predictable response to imatinib? // Pigment Cell Melanoma Res. ‒ 2011. ‒ T. 24, № 2. ‒ C. 390-2.